Income Tax: What precautions should you take while filing your ITR?
1. Select your tax regime: First, you need to carefully select your income tax regime. You may want to use an income tax calculator to compare the tax computed under both regimes before you take the final call.
2. Download documents: You need to download AIS and Form 26AS and check the actual TDS / TCS / tax paid. If you happen to find any discrepancy, you must reconcile it with the employer/ tax deductor/ bank.
3. Study the documents: Now you can compile and carefully study the documents to be referred to when filing your ITR. These include documents such as bank statement/ passbook, interest certificates, receipts to claim exemptions or deductions, Form 16, Form 26AS (Annual Information Statement), investment proofs, etc.
4. Check authenticity: Now, you need to make sure that the other salient details, including PAN, permanent address, contact details, and bank account details, are correct in the pre-filled data.
5. Choose the correct form: It is also important to identify the correct return form for you, from ITR-1 to ITR-7.
Read this Livemint article to check which ITR form will be applicable.
6. Provide details: Make sure you provide all the details in the return, such as total income, deductions (if any), interest (if any), taxes paid / collected (if any), etc. It is important to make sure that no documents are attached along with ITR-1.
7. Before deadline: E-file the income return on or before the due date, which is September 15, 2025. Late returns have adverse consequences, including late filing fees, losses not being carried forward, and deductions and exemptions not being available.
8. E-verify the return: After e-filing the return, make sure to e-verify it. If you want to manually verify your return, send the signed physical copy of ITR-V Acknowledgement (by speed post) within the appropriate timelines of filing the return to Centralised Processing Centre, Income Tax Department, Bengaluru 560500 (Karnataka).
For all personal finance updates, visit here
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
2 hours ago
- India.com
Mind‑Boggling Rs 1 Septillion Deposit To Dead Woman's Bank Account Sparks Meme-Fest, Bank Denies Claim
In what seemed like a bizarre twist of fate, a 20-year-old man from Unchi Dankaur village in Greater Noida was stunned to discover an astronomical amount credited to his late mother's Kotak Mahindra Bank account, a jaw-dropping figure of Rupees 1.13 lakh crore. The incident quickly went viral, with social media users joking that the man had overnight become richer than Elon Musk, Ambani, and even several nations combined. Memes poured in, and netizens dubbed him the 'richest Indian in history.' The enormous number nearing a septillion rupees was far beyond any realistic banking transaction. Deepak, who hails from a modest background, said he was simply trying to access the account for closure after his mother's death not expecting to be swept up in a national media frenzy. The man, Deepak, had checked the account two months after the death of his mother, Gayatri Devi, and was shocked to see the massive credited amount. Unsure of how to react, he reached out to local media, and within hours, the news was all over the internet, reportedly. However, Kotak Mahindra Bank quickly issued a clarification, calling the reports 'false and misleading'. The bank stated that there was no technical glitch and that the viral screenshot was inaccurate. The account has been frozen, and the matter has been reported to the Income Tax Department for investigation. While there's no official explanation yet, experts suspect a possible display error or a data glitch at the user interface level, though no official technical explanation has been provided yet. Such simiar incidents have occurred in the past in India and abroad where ATM receipts or mobile apps displayed unrealistically high balances due to technical issues, reportedly.
Time of India
2 hours ago
- Time of India
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan , executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Live Events Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.' Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries , Cipla , Mankind Pharma , Torrent Pharmaceuticals , and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
Economic Times
2 hours ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
